Shalini Sharp - 06 Jun 2022 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Reporting relationship: Director
Issuer ticker: STRO
Reported as of: 06 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2022, 19:10:03 UTC
Prior SEC filing: 20 May 2022
Next SEC filing: 14 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Edward C. Albini as attorney-in-fact

Key filing fact

Shalini Sharp filed Form 4 for SUTRO BIOPHARMA, INC. (STRO) on 08 Jun 2022.

Key facts

This page summarizes Shalini Sharp's Form 4 filing for SUTRO BIOPHARMA, INC. (STRO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2022, 19:10.

Change

Previous filing in this sequence was filed on 20 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STRO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +18,500
Change %
Price: $0.000000
Shares after: 18,500
Date: 06 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,500
Exercise price: $4.44
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.